<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460235</url>
  </required_header>
  <id_info>
    <org_study_id>HEMATOVAC</org_study_id>
    <nct_id>NCT04460235</nct_id>
  </id_info>
  <brief_title>Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma</brief_title>
  <acronym>HEMATOVAC</acronym>
  <official_title>Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French Public Health Council recommended pneumococcal vaccination combined strategy for&#xD;
      all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent&#xD;
      pneumococcal injection followed 2 months later by polysaccharide 23-valent vaccine injection.&#xD;
      General practitioners are usually in charge of this vaccination. Conjugated pneumococcal&#xD;
      vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and&#xD;
      lymphoma are treated with multiple courses of chemotherapy, impairing the immune system and&#xD;
      potentially the response to vaccination. These patients are more at risk for developing&#xD;
      pneumococcal invasive diseases than the general population. However, efficacy of pneumococcal&#xD;
      vaccination is poorly documented in this setting. We assume that 70% of the patients are&#xD;
      non-responders to vaccination, according to their anti-pneumococcal immunoglobulin G titers&#xD;
      and the opsonophagocytic activity. To assess the immunogenicity of the pneumococcal&#xD;
      vaccination combined strategy in adult population of acute leukemia and lymphoma, the&#xD;
      investigator will measure anti-pneumococcal serotype-specific immunoglobulin G titers and&#xD;
      opsonophagocytic activity at different time-points after completion of the combined vaccine&#xD;
      strategy. The primary objective is to assess the immunogenicity of pneumococcal vaccination&#xD;
      combined strategy at 3 months after the 13-valent pneumococcal injection (corresponding to 1&#xD;
      month after the end of the combined strategy) using immunoglobulin G titers and&#xD;
      opsonophagocytic activity. At different time points (day 0, 1 month after the 13-valent&#xD;
      pneumococcal injection, the day of the injection of the polysaccharide 23-valent vaccine, one&#xD;
      month after the injection of the polysaccharide 23-valent vaccine, 3-6 months after the&#xD;
      polysaccharide 23-valent vaccine,9-12 months after the polysaccharide 23-valent vaccine), the&#xD;
      immunological response to vaccination will be monitored using specific-serotype&#xD;
      immunoglobulin G titers, opsonophagocytic activity, and total anti-pneumococcal&#xD;
      Immunoglobulin. The investigator will determine predictive factors of non-response to&#xD;
      vaccination by comparing demographic data, biological data and treatment received by both&#xD;
      acute myeloblastic leukemia and lymphoma patients. The tolerance and safety of the&#xD;
      vaccination strategy will also be assessed in this specific hematological population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having a good response to combined strategy</measure>
    <time_frame>39 months</time_frame>
    <description>Proportion of patients having a good response to combined strategy at 4 weeks after the end of the combined strategy. A good response to vaccination is defined by 4/7 tested serotypes responding to these 4 criteria: a serotype-specific immunoglobulin G titer ≥ 1μg/L (WHO threshold), a two-fold increase of this immunoglobulin G titer compare to baseline before vaccination, a serotype-specific opsonophagocytic activity ≥1/8, and a four-fold increase of functional antibodies compare to baseline.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Vaccine</condition>
  <condition>Streptococcus Pneumoniae</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Vaccination</arm_group_label>
    <description>All patients will be vaccinated</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with hematological malignancies like acute myeloblastic leukemia or non&#xD;
        Hodgkin lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 year-old.&#xD;
&#xD;
          -  AND medical follow-up in hematology unit&#xD;
&#xD;
          -  AND had received a first course of chemotherapy for acute myeloblastic leukemia&#xD;
             without ProMyelogenousLeukemia-RetinoicAcidReceptor alpha and no planned allogeneic&#xD;
             hematopoietic stem cell transplantation or for diffuse large B cell lymphoma or for&#xD;
             follicular lymphoma&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Having signed the consent form.&#xD;
&#xD;
          -  Having an health insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving monoclonal antibodies or biotherapies altering the immune response, other&#xD;
             than anti-Cluster of differentiation number 20 antibodies in the chemotherapy&#xD;
             protocol.&#xD;
&#xD;
          -  Previous vaccination with 13-valent pneumococcal vaccine or polysaccharide 23-valent&#xD;
             vaccine (unless 13-valent pneumococcal vaccine was administered in childhood. The last&#xD;
             injection must be performed at least five years ago).&#xD;
&#xD;
          -  Preexisting condition that altered the immune response: splenectomy, HIV, primary or&#xD;
             secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune&#xD;
             disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not&#xD;
             included in the chemotherapy.&#xD;
&#xD;
          -  Patient who already received chemotherapy for malignancy in the previous 2 years&#xD;
             before the inclusion.&#xD;
&#xD;
          -  Allogeneic hematopoietic stem cell transplantation planned in the following 3 months&#xD;
             after the first chemotherapy course.&#xD;
&#xD;
          -  Curative anticoagulation within 7 days before vaccination.&#xD;
&#xD;
          -  Major blood clotting disorders preventing intramuscular injection.&#xD;
&#xD;
          -  Medical history of anaphylactic reaction to vaccination.&#xD;
&#xD;
          -  Known allergy to one of the vaccine components.&#xD;
&#xD;
          -  Involvement to another vaccine biomedical research.&#xD;
&#xD;
          -  Protected person.&#xD;
&#xD;
          -  Pregnant women or women of childbearing age without appropriate contraceptive&#xD;
             measures.&#xD;
&#xD;
          -  Perfusion of polyvalent immunoglobulins during follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu Puyade, MD, PhD</last_name>
    <phone>0033 5 49 44 32 76</phone>
    <email>mathieu.puyade@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fanny Abriat</last_name>
    <phone>0033 5 49 44 37 96</phone>
    <email>fanny.abriat@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François-Xavier GROS, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud JACCARD, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Pilar GALLEGO HERNANZ, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine MACHET, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

